723 related articles for article (PubMed ID: 31874279)
1. Oncogenic signaling pathways associated with immune evasion and resistance to immune checkpoint inhibitors in cancer.
Kobayashi Y; Lim SO; Yamaguchi H
Semin Cancer Biol; 2020 Oct; 65():51-64. PubMed ID: 31874279
[TBL] [Abstract][Full Text] [Related]
2. Immuno-Metabolism: The Role of Cancer Niche in Immune Checkpoint Inhibitor Resistance.
Weng CY; Kao CX; Chang TS; Huang YH
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33514004
[TBL] [Abstract][Full Text] [Related]
3. Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance.
Li Y; Liu J; Gao L; Liu Y; Meng F; Li X; Qin FX
Immunol Lett; 2020 Apr; 220():88-96. PubMed ID: 30885690
[TBL] [Abstract][Full Text] [Related]
4. Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors.
Yao L; Jia G; Lu L; Bao Y; Ma W
Int Immunopharmacol; 2020 Aug; 85():106628. PubMed ID: 32474388
[TBL] [Abstract][Full Text] [Related]
5. Understanding genetic determinants of resistance to immune checkpoint blockers.
Aspeslagh S; Chabanon RM; Champiat S; Postel-Vinay S
Semin Cancer Biol; 2020 Oct; 65():123-139. PubMed ID: 31881338
[TBL] [Abstract][Full Text] [Related]
6. Immune Checkpoint Inhibitors in Hepatocellular Cancer: Current Understanding on Mechanisms of Resistance and Biomarkers of Response to Treatment.
Onuma AE; Zhang H; Huang H; Williams TM; Noonan A; Tsung A
Gene Expr; 2020 Jun; 20(1):53-65. PubMed ID: 32340652
[TBL] [Abstract][Full Text] [Related]
7. Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment.
Song Y; Fu Y; Xie Q; Zhu B; Wang J; Zhang B
Front Immunol; 2020; 11():1956. PubMed ID: 32983126
[TBL] [Abstract][Full Text] [Related]
8. HLA genotyping meets response to immune checkpoint inhibitors prediction: A story just started.
Ivanova M; Shivarov V
Int J Immunogenet; 2021 Apr; 48(2):193-200. PubMed ID: 33112034
[TBL] [Abstract][Full Text] [Related]
9. Addressing resistance to immune checkpoint inhibitor therapy: an urgent unmet need.
Hu-Lieskovan S; Malouf GG; Jacobs I; Chou J; Liu L; Johnson ML
Future Oncol; 2021 Apr; 17(11):1401-1439. PubMed ID: 33475012
[TBL] [Abstract][Full Text] [Related]
10. Modulation of gut microbiota to overcome resistance to immune checkpoint blockade in cancer immunotherapy.
Huang J; Jiang Z; Wang Y; Fan X; Cai J; Yao X; Liu L; Huang J; He J; Xie C; Wu Q; Cao Y; Leung EL
Curr Opin Pharmacol; 2020 Oct; 54():1-10. PubMed ID: 32619934
[TBL] [Abstract][Full Text] [Related]
11. Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion.
Jiang Y; Zhan H
Cancer Lett; 2020 Jan; 468():72-81. PubMed ID: 31605776
[TBL] [Abstract][Full Text] [Related]
12. Immune Checkpoint Inhibitors: A Promising Treatment Option for Metastatic Castration-Resistant Prostate Cancer?
Ruiz de Porras V; Pardo JC; Notario L; Etxaniz O; Font A
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946818
[TBL] [Abstract][Full Text] [Related]
13. Alterations in TP53 Are a Potential Biomarker of Bladder Cancer Patients Who Benefit From Immune Checkpoint Inhibition.
Lyu Q; Lin A; Cao M; Xu A; Luo P; Zhang J
Cancer Control; 2020; 27(1):1073274820976665. PubMed ID: 33356494
[TBL] [Abstract][Full Text] [Related]
14. Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance.
Bagchi S; Yuan R; Engleman EG
Annu Rev Pathol; 2021 Jan; 16():223-249. PubMed ID: 33197221
[TBL] [Abstract][Full Text] [Related]
15. The Current Landscape of Immune Checkpoint Blockade in Metastatic Lung Squamous Cell Carcinoma.
Yuan H; Liu J; Zhang J
Molecules; 2021 Mar; 26(5):. PubMed ID: 33807509
[TBL] [Abstract][Full Text] [Related]
16. YY1 regulates cancer cell immune resistance by modulating PD-L1 expression.
Hays E; Bonavida B
Drug Resist Updat; 2019 Mar; 43():10-28. PubMed ID: 31005030
[TBL] [Abstract][Full Text] [Related]
17. Immune-checkpoint inhibitor resistance in cancer treatment: Current progress and future directions.
Zhang C; Zhang C; Wang H
Cancer Lett; 2023 May; 562():216182. PubMed ID: 37076040
[TBL] [Abstract][Full Text] [Related]
18. News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors.
Melaiu O; Lucarini V; Giovannoni R; Fruci D; Gemignani F
Semin Cancer Biol; 2022 Feb; 79():18-43. PubMed ID: 32659257
[TBL] [Abstract][Full Text] [Related]
19. Treg-mediated acquired resistance to immune checkpoint inhibitors.
Saleh R; Elkord E
Cancer Lett; 2019 Aug; 457():168-179. PubMed ID: 31078738
[TBL] [Abstract][Full Text] [Related]
20. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).
Hsu PC; Jablons DM; Yang CT; You L
Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
